REQUEST FORM

VeriSeq Premium® Cod. 16207 💸 BIOCLINICA





Customer	code:	
----------	-------	--

Last name: *Name:			ne:	*Bir			irth date: d	d/mm/yyyy
Patient Id.:		kg):		ht (cm):			****	
				int (ciri).				
Address:								
Country:		City:				ZIP co	de:	
LOOD SAMPLE								
Date of draw:		*Time of draw		•••••				
BSTETRIC HISTORY								
umber of previous deliveries:	Num	ber previous miso	carriages:	Number of abortions:				
ate of last birth/abortion or miscarr	riage (month/year): mm/yyyy History of pregnancies with chromosomal abnormalities or genetic disease					ities or genetic diseases		
lumber of previous anomalous pregi	nancies:							
ASON FOR REFERRAL								
☐ First trimester biochemical screenin	g 🗆 Adva	anced maternal ag	ge 🗆 Ultraso	und finding	gs suggestiv	e of chromo	osomal abnorr	malities Anxiety
SCLOSURE OF FETAL GENDER								
Yes, I wish to know the fetal gender (c	lefault optio	n) 🗆 No, I don't	want to know t	ne fetal gen	nder (If	no checkbo	k is ticked, feta	I sex is provided by defau
RRENT PREGNANCY								
Gestational age (weeks/days):		Meth	nod to determ	ine gestati	ional age:			
F PREGNANCY: Yes No If IVF, own eggs: Yes No			If egg donation, indicate donator's age: dd/mm/yyyy					
		ogate mother ☐ Yes ☐ No		date of eggs' collection:				
TRASOUND INFORMATION								
ate of last ultrasound:		Gestational age by	y ultrasound (\	Veeks/day	/s):			
Type of pregnancy: ☐ 1 fetus	Fetal measurements: ☐ Norm			nal \square Fetus smaller than gestational age \square Fetus bigger than gestational age				
] Undone	☐ with abnormal	ities (specify:)
1orphological study: ☐ Normal ☐								
REENING PREVIO DE TRISOMÍA 2:		oiochemical test	☐ 2nd trir	nester bio	chemical to	est	□ No	
CREENING PREVIO DE TRISOMÍA 2:	trimester b		☐ 2nd trir					y of genetic disease
CREENING PREVIO DE TRISOMÍA 2:	trimester b	nical test	_				Family histor	y of genetic disease
CREENING PREVIO DE TRISOMÍA 2: ☐ Yes Test type: ☐ TN + T1st ☐ 1st trimes ☐ 2nd trime	trimester bester biochen	nical test	☐ Combin				Family histor	
CREENING PREVIO DE TRISOMÍA 2: Yes Test type: TN + T1st 1st trimes 2nd trime Only TN 1st	trimester b ster biochen ester ultraso st T (or other	nical test und markers ultrasound markers	□ Combin				Family histor	
CREENING PREVIO DE TRISOMÍA 2: Yes Test type: TN + T1st 1st trimes 2nd trime Only TN 1st	ster biochen ester ultraso st T (or other	nical test und markers ultrasound markers	□ Combins)	ed test: 1s	and 2nd	trimester	Family histor Carrier of a g	
☐ 1st trimes ☐ 2nd trime	ster biochen ester ultraso st T (or other	nical test und markers ultrasound markers	□ Combinss)	ed test: 1s	Email:	trimester	Family histor Carrier of a g	genetic disease

dd/mm/yyyy

Place, Date

Page 1/2

TEST INFORMATION AND CONSENT FORM





Required fields are marked with an asterisk (*)

Test limitations

- 1. Although the latest research data indicate that the test is highly accurate, with a detection rate of trisomy 21 close to 100% and a false positive rate of less than 1%, this test can not be considered diagnostic. It should only be considered as a very efficient screening test. Therefore, an abnormal result must always be confirmed by an invasive prenatal test, and a normal result can not exclude with total certainty an affected fetus due to these pathologies. This is due to several limitations of the current methodology.
- 2. This test is designed as screening for chromosomal aneuploidies and is validated for chromosomes 13, 18, 21, X and Y. It has been validated for single and twin pregnancies with a gestational age of 10 weeks or more. Currently, in twin pregnancies, sex chromosome aneuploidies cannot be detected. Through the used test, no other possible chromosomal, subchromosomal or genetic alterations are detected. A false positive or negative may occur due to the presence of maternal chromosomal alterations, a high maternal body mass index, confined placental mosaicism, or the existence of an evanescent/deferred twin (see yield table).
- 3. If the pregnant mother has received an allogeneic blood transfusion, transplant or stem cell therapy, there is a possibility of non-interpretable results due to the presence of exogenous DNA.

- 1. I fully understand the indication of the test, the objective, its characteristics and potential risks of this test. My doctor, Dr . *....., has answered all my questions about it.
- 2. I fully understand the limitations of this test, in particular that the detection rate of the changes studied (chromosome 13, 18, 21, X and Y) is close but is NOT 100%. In cases of twin pregnancies, only trisomies of chromosomes 13, 18 and 21 and presence of the Y chromosome can be reported.
- 3. I confirm all the provided information about me is true and correct.
- 4. I understand that test result will be ready in about 10 days from when the lab receives the sample, but it could be ready in less time.
- 5. I was informed that it may be necessary to re-provide blood (<1% of cases).
- 6. I understand that the results are reference values and do not represent an element of clinical diagnosis. The results obtained should be considered in the context together with other clinical criteria, so it is recommended that these results be communicated in medical consultation.
- 7. I agree to provide information about my pregnancy, especially if my future baby is affected by some kind of genetic disease. I understand and authorize my doctor to contact me to know this information.
- 8. I give my consent for the use of clinical data by my laboratory for auditing, quality assurance and research purposes, provided that my person remains anonymous and not identifiable, and all the information I have provided is excluded from any publication. I can exercise my rights and revoke that consent at any time by contacting my laboratory.
- 9. About personal data: According to Spanish Law 41/2002, regulating Patient Autonomy, and Spanish Law 3/2018 on the Protection of Personal Data, The test applicant must have the written consent of the patient (and/or their legal representatives) to carry out this test and the treatment of their personal data. The information collected in this form will be incorporated into a confidential automated file registered in the Spanish Agency for the Protection of Data, under the terms established in Spanish Law 3/2018, with the purpose of carrying out the genetic study requested here. The patient, or their legal representatives, may at any time exercise their rights of access, rectification, deletion, limitation, opposition and portability by requesting it through his/her laboratory.

* Patient's name and last name:	* Patient's signature:	* Place and date:
* Healthcare professional prescriber name:	* Healthcare professional prescriber signature:	* Place and date: